$4.47
2.05% yesterday
Nasdaq, Nov 26, 10:00 pm CET
ISIN
US2826442020
Symbol
EKSO

Ekso Bionics Holdings, Inc. Stock price

$4.47
-0.45 9.15% 1M
+0.27 6.50% 6M
-4.68 51.15% YTD
-5.61 55.67% 1Y
-12.18 73.15% 3Y
-81.48 94.80% 5Y
-2,106.03 99.79% 10Y
-3,696.78 99.88% 20Y
Nasdaq, Closing price Wed, Nov 26 2025
+0.09 2.05%

Key metrics

Basic
Market capitalization
$15.2m
Enterprise Value
$16.7m
Net debt
$1.5m
Cash
$2.7m
Shares outstanding
2.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.0 | 0.9
EV/Sales
1.1 | 1.0
EV/FCF
negative
P/B
1.6
Financial Health
Equity Ratio
47.7%
Return on Equity
-89.2%
ROCE
-85.4%
ROIC
-
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$14.8m | $16.9m
EBITDA
$-9.4m | -
EBIT
$-10.9m | $-11.1m
Net Income
$-10.7m | $-11.9m
Free Cash Flow
$-9.0m
Growth (TTM | estimate)
Revenue
-16.6% | -5.5%
EBITDA
4.5% | -
EBIT
7.0% | -5.8%
Net Income
4.2% | -4.8%
Free Cash Flow
10.6%
Margin (TTM | estimate)
Gross
53.5%
EBITDA
-63.4% | -
EBIT
-73.7%
Net
-72.3% | -70.0%
Free Cash Flow
-60.9%
More
EPS
$-4.1
FCF per Share
$-3.4
Short interest
3.6%
Employees
64
Rev per Employee
$280.0k
Show more

Is Ekso Bionics Holdings, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,049 stocks worldwide.

Ekso Bionics Holdings, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Ekso Bionics Holdings, Inc. forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Ekso Bionics Holdings, Inc. forecast:

Buy
88%
Hold
13%

Financial data from Ekso Bionics Holdings, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
15 15
17% 17%
100%
- Direct Costs 6.86 6.86
19% 19%
47%
7.89 7.89
14% 14%
53%
- Selling and Administrative Expenses 16 16
6% 6%
105%
- Research and Development Expense 3.24 3.24
25% 25%
22%
-9.35 -9.35
4% 4%
-63%
- Depreciation and Amortization 1.52 1.52
20% 20%
10%
EBIT (Operating Income) EBIT -11 -11
7% 7%
-74%
Net Profit -11 -11
4% 4%
-72%

In millions USD.

Don't miss a Thing! We will send you all news about Ekso Bionics Holdings, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ekso Bionics Holdings, Inc. Stock News

Neutral
GlobeNewsWire
29 days ago
SAN RAFAEL, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that on October 28, 2025, it entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 769,490 shares of the Company's common stock at a pu...
Neutral
GlobeNewsWire
29 days ago
SAN RAFAEL, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and nine months ended September 30, 2025.
Neutral
Seeking Alpha
4 months ago
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q2 2025 Earnings Conference Call July 28, 2025 4:30 PM ET Company Participants Jerome Wong - CFO & Corporate Secretary Scott G. Davis - CEO & Director Stephen Kilmer - Corporate Participant Conference Call Participants Benjamin Charles Haynor - Lake Street Capital Markets, LLC, Research Division Swayampakula Ramakanth - H.C.
More Ekso Bionics Holdings, Inc. News

Company Profile

Ekso Bionics Holdings, Inc. engages in the design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. It operates through the following business segments: EksoHealth, EksoWorks, and Other. The EksoHealth segment consists of the engineering, manufacture, and sale of exoskeletons for applications in the medical markets. The EksoWorks segment offers exoskeleton devices to allow able-bodied users to perform heavy duty work for extended periods. The company was founded on January 30, 2012 and is headquartered in Richmond, CA.

Head office United States
CEO Scott Davis
Employees 64
Founded 2012
Website eksobionics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today